Page results
-
The UCLH Maternity Voices Partnership (MVP) is a team of women and their families, commissioners and providers (midwives and doctors) working together to review and contribute to the development of local maternity care.
-
A group to share ideas about managing exams and assessments when a health condition gets in the way.
-
The Maternal Medicine team provides care for women with pre-existing medical disorders or pregnancy-related medical conditions. We work in a multidisciplinary team of doctors and midwives in order to provide the best standard of care for women and their babies.
-
How we use your information at UCLH: what you need to know.
-
This is a speech and language therapy service for deaf or hard of hearing adults who are having communication difficulties because of a hearing loss. The primary focus of the service is to help with spoken English skills.
-
This page is for parents, carers and family members who are acting as comforters and carers for children and young people having radioactive iodine (131I) treatment. It explains what the treatment involves, how to prepare for it and what you can expect afterwards.
-
We are now administering new COVID-19 treatments for patients at highest risk in the community. The service can prescribe oral antivirals to be taken at home, and give intravenous antibody treatments at the hospital.
-
Alternatives to Accident and Emergency (A&E) and attending the Emergency Department (Casualty) at UCLH
-
Dr Zandi is a consultant neurologist. He works on central and peripheral nervous system neuroimmunological diseases, particularly autoimmune encephalitis (eg. associated with NMDAR, LGI1 or related autoantibodies, COVID-19 neurology), with a broader research interest in all central and peripheral neuroimmunology, CNS vasculitis and amyloid related angiopathy, neurological involvement in systemic lupus erythematosus and related rheumatological conditions.
-
The COVID Medicines Delivery Unit (CMDU gives new COVID-19 treatments for patients at highest risk in the community from the NCL sector. These treatments involve intravenous infustion of neutralising monoclonal antibodies (nMABs) or oral antiviral treatments, which are given to high-risk patients who have had a positive PCR test.
File results
-
FOI/2022/0024 - Protocols for major haemorrhaging in hospital
-
FOI/2022/0026 - Patients referred for puberty blockers/ services related to gender identity
-
FOI/2022/0029 - Treatment and charges for overseas visitors and migrants
-
FOI/2022/0040 - Agency spend for doctors, nurses and allied health professionals
-
FOI/2022/0048 - Cancer deaths in relation to Covid-19
-
FOI/2022/0069 - Trust’s flexible endoscope inventory
-
FOI/2022/0094 - Emergency Covid funding - private FM contractors
-
FOI/2022/0114 - Number of new diagnoses relating to various conditions
-
FOI/2022/0118 - Contact centre/ Call centre contracts
-
FOI/2022/0150 - Hepatocellular carcinoma drug treatments